Our major areas of research focus are in synthetic medicinal chemistry, structure-based drug design, fragment screening and academic drug discovery.
Our research strengths also include peptide science, chemical-biology and computational chemistry.
We headquarter the ARC Training Centre for Fragment Based Design, a national training centre with collaborators from Griffith University and the University of Sydney and research partners including CSIRO, Takeda, and Vernalis. We are also home to the Australian Translational Medicinal Chemistry Facility.
Historically, our achievements include Zanamivir (Relenza®), a first in-class antiviral drug developed to treat and prevent influenza. More recently we have spun out start-ups including Cincera and Inosi Therapeutics to develop novel agents to treat metabolic disease and fibrosis.